Evidence map›Paper›PMID 33733326›Full record

ArticleInternational archives of occupational and environmental health2021

Evaluation of a safe infusion device on reducing occupational exposure of nurses to antineoplastic drugs: a comparative prospective study. Contamoins-1.

Fabien Forges, Emeline Blanc, Bastien Raymond, Sandrine Menguy, Agnès Macé, Marion Hugues, Corinne Macron, Wafa Bouleftour, Fabien Tinquaut, Jérôme Guitton and 1 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in International archives of occupational and environmental health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Safe handling of hazardous drugs.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Fabien ForgesDépartement de Pharmacie, Institut de Cancérologie Lucien Neuwirth, 108 bis avenue Albert Raimond, 42270, Saint-Priest-en-Jarez, France. fabien.forges@icloire.fr.
Emeline BlancDirection de La Recherche Clinique Et de L'Innovation, Hospices Civils de Lyon, 3 quai des Célestins, Cedex 2, 69229, Lyon, France.
Bastien RaymondDépartement de Pharmacie, Institut de Cancérologie Lucien Neuwirth, 108 bis avenue Albert Raimond, 42270, Saint-Priest-en-Jarez, France.
Sandrine MenguyDépartement de Pharmacie, Institut de Cancérologie Lucien Neuwirth, 108 bis avenue Albert Raimond, 42270, Saint-Priest-en-Jarez, France.
Agnès MacéDépartement de Pharmacie, Institut de Cancérologie Lucien Neuwirth, 108 bis avenue Albert Raimond, 42270, Saint-Priest-en-Jarez, France.
Marion HuguesDépartement de Pharmacie, Institut de Cancérologie Lucien Neuwirth, 108 bis avenue Albert Raimond, 42270, Saint-Priest-en-Jarez, France.
Corinne MacronDirection Des Soins, Institut de Cancérologie Lucien Neuwirth, 108 bis avenue Albert Raimond, 42270, Saint-Priest-en-Jarez, France.
Wafa BouleftourDépartement D'oncologie Médicale, Institut de Cancérologie Lucien Neuwirth, 108 bis avenue Albert Raimond, 42270, Saint-Priest-en-Jarez, France.
Fabien TinquautDépartement de Santé Publique, Institut de Cancérologie Lucien Neuwirth, 108 bis avenue Albert Raimond, 42270, Saint-Priest-en-Jarez, France.
Jérôme GuittonLaboratoire de Biochimie-Toxicologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69310, Pierre Bénite, France.
Xavier SimoënsDépartement de Pharmacie, Institut de Cancérologie Lucien Neuwirth, 108 bis avenue Albert Raimond, 42270, Saint-Priest-en-Jarez, France.
Institute Cancer De La Loire Lucien Neuwirth · FRHôpital Lyon Sud · FRHospices Civils de Lyon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDespite the decreasing of environmental contamination throughout the anticancer drug circuit, the administration of chemotherapies remains at risk of occupational exposure for nurses. Many medical devices aim at securing administration, but none have been scientifically evaluated to verify the actual improvement.

methodsA monocentric comparative before/after study was carried out in an oncology day hospital to evaluate the efficacy of Safe Infusion Devices in reducing drug exposure compared to usual infusion practices. The rate of nurses' gloves contamination was estimated. To avoid false negatives and to ensure sampling reproducibility, each sample of gloves was contaminated with a drop of topotecan. Association between contamination and other variables was investigated using a multivariate logistic regression analysis.

resultsThe usual practice led to a rate of 58.3% of contaminated samples while Safe Infusion Devices to a rate of 15%: Safe Infusion Devices reduced the risk of gloves contamination by 85% in multivariate analysis (Odds ratio = 0.15; 95% confidence interval = 0.05-0.46; p < 0.001). Topotecan was identified in 100% of the samples. Only one case of cross-contamination has occurred.

conclusionDespite the current practice of using neutral solvent-purged infusers, the occupational exposure remains high for nurses and Safe Infusion Devices significantly reduced this risk of exposure. However, glove contamination is only a surrogate endpoint. The results confirmed that the disconnection of empty bags resulted in occupational exposure. Except a contamination due to the leakage of a bag, no cross-contamination was detected. Safe Infusion Devices were highly effective but did not completely eliminate exposure.

Indexed as

NursesAntineoplastic AgentsCyclophosphamideGloves, ProtectiveHumansInfusions, IntravenousIrinotecanOccupational ExposurePemetrexedTopotecanAntineoplastic AgentsCyclophosphamideIrinotecanPemetrexedTopotecanAntineoplastic agentsCancerDrug administrationInfusion deviceNursingOccupational exposure

Identifiers

PMID33733326
OpenAlexW3138829571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.